phase iii thor study: erdafitinib vs. pembrolizumab in fgfr-altered advanced or metastatic uc
Published 9 months ago • 321 plays • Length 3:37Download video MP4
Download video MP3
Similar videos
-
1:04
thor: erdafitinib in advanced or metastatic urothelial cancer and fgfr alterations
-
1:47
thor: erdafitinib in metastatic urothelial cancer with fgfr alterations
-
2:31
an update on erdafitinib for metastatic/uresectable fgfr alteration urothelial carcinoma
-
2:20
erdafitinib /- cetrelimab in muc patients with fgfr alterations
-
1:09
futibatinib plus pembrolizumab for the treatment of advanced or metastatic urothelial carcinoma
-
1:49
blc2001: erdafitinib for the treatment of metastatic urothelial carcinoma
-
1:27
erdafitinib and enfortumab vedotin in pretreated fgfr2/3-mutant bladder cancer
-
0:49
evolving landscape of urothelial cancer treatment: erdafitinib or enfortumab vedotin?
-
2:12
erdafitinib: one more tool for bladder cancer
-
6:09
erdafitinib (erda) or erda plus cetrelimab for patients with metastatic or locally advanced urot...
-
0:34
pembrolizumab plus enfortumab vedotin for bladder cancer
-
1:28
erdafitinib for bladder cancer: more to come following fda approval
-
20:21
targeted therapy for the treatment of advanced metastatic urothelial cancer youtube
-
2:04
results of a phase ii study of lhrh therapy in high-risk prostate cancer
-
1:48
what does the 2-year follow-up tell us about the use of pembrolizumab for advanced bladder cancer?
-
1:14
bladder: enfortumab vedotin pembrolizumab & vesper trial
-
6:01
enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancer